Congress Blocks White House Plan to Politicize Federal Research Grants, for Now

Imagine you are a hospital administrator trying to plan a five-year clinical trial for a new cancer therapy. Now imagine that at any point, a political appointee in Washington could cancel your funding, not because the science failed, but because someone decided your research no longer fits the administration's priorities. That is the scenario hundreds of thousands of researchers, doctors and hospital leaders spent this summer trying to prevent.

They got a reprieve this week. On Tuesday, the House passed a short-term government funding bill by a vote of 370-48, following the Senate's overwhelming 90-6 approval in early August. President Trump is expected to sign it. Tucked inside the routine spending measure, which keeps the government funded at current levels through Dec. 11, is a provision that blocks a White House proposal that would have fundamentally rewritten how federal research money gets awarded and managed.

The provision does not kill the proposal outright. It delays it, pushing the fight past the midterm elections and setting up another confrontation when the current funding measure expires in December.

What the Blocked Rule Would Have Done

To understand why this fight drew such fierce opposition, it helps to know what the Office of Management and Budget was actually proposing. Back in late May, OMB released a draft rule to overhaul the Uniform Guidance, the federal rulebook governing roughly $200 billion a year in the grants that fund everything from university cancer labs to rural hospital residency programs. Think of the Uniform Guidance as the operating manual for how the government hands out research money. This rewrite would have added a new step: political appointees in the Trump administration would need to sign off on every new grant, checking whether it "advances the President's policy priorities."

That is a significant departure from how federal science funding has traditionally worked. For decades, grants have been awarded largely through peer review, where scientists evaluate other scientists' proposals based on merit, feasibility and public health value. Under the proposed rule, political appointees would also be empowered to block funding for research they viewed as promoting diversity, equity and inclusion principles, or denying what the administration calls "the biological reality of the sex binary." Existing grants, not just new ones, would have been more vulnerable to modification or cancellation mid-project.

OMB defended the plan as a way to "improve transparency, accountability, and oversight for Federal awards." But the public response suggested most people who work in or depend on federally funded science saw it very differently. When the public comment period closed on July 13, OMB had received 496,805 submissions. A STAT News analysis of 52,000 posted comments found the overwhelming majority opposed the rule.

The list of objectors reads like a roll call of American medicine and research. The American Hospital Association warned that "substantial uncertainty" from the rule would discourage hospitals from recruiting investigators, launching multiyear clinical studies or expanding residency and community health programs. "Federal financial assistance succeeds because recipients have confidence that they can responsibly invest in programs that often require years to produce measurable public benefits," the AHA wrote in July. Preserving that predictability, the group argued, is not the opposite of accountability. It is what makes accountability possible.

AcademyHealth, a nonpartisan health policy research organization, went further, warning the rule would give political appointees "authority to block federally funded research on ideological grounds" and "prohibit entire categories of health services inquiry." Research!America cautioned it would "weaken the role of expert scientific review in funding decisions" and have "a chilling effect on health disparities research." The American Academy of Nursing said the changes would "weaken scientific peer review, allow politically driven funding and grant termination decisions" and restrict international collaboration.

Perhaps the starkest warning came from Elizabeth Ginexi, a scientist with three decades of research experience and a former NIH Scientific Program Official. In her public comment, she called the proposal "the most consequential attack on American science and on the integrity of federal grantmaking in the postwar era." She warned it would let any active grant be terminated mid-project "for undefined political reasons" and would ban journal subscriptions and publication costs that have been standard practice for more than fifty years.

The Infectious Diseases Society of America and the HIV Medicine Association echoed those fears after the bill's passage, warning the rule would "replace peer review, scientific merit and patient needs with political alignment" and leave the country "far more vulnerable to infectious diseases." The American Cancer Society Cancer Action Network struck a similar note, with president Lisa Lacasse saying the delay allows the National Institutes of Health and National Cancer Institute "to continue their critical work without unnecessary disruption," since "every delay in research is a delay in new treatments and new hope."

The political dynamics here cut across the usual partisan lines. Senate Appropriations Chair Susan Collins, a Maine Republican, said she was "pleased" the bipartisan agreement kept the rule from taking effect, noting she had pushed for changes in a July 6 letter warning of harm to "small, rural communities, families, and biomedical research." Alaska Sen. Lisa Murkowski also backed the block. Every Senate Democrat had earlier demanded OMB rescind the rule entirely, arguing it exceeded the agency's statutory authority and infringed on Congress's constitutional power over federal spending.

Senate Appropriations Vice Chair Patty Murray, a Washington Democrat, framed the outcome as partial progress rather than victory. "This bill blocks implementation of OMB's corrupt new grants rule for the duration of the CR," she said, but noted Republicans "rejected killing the proposed rule outright." She vowed to "keep fighting to put a stop to it once and for all."

Why It Matters

This is not an abstract bureaucratic squabble. Federal grants fund the hospital trials that test new treatments, the training programs that produce the next generation of nurses and doctors, and the public health research that tracks emerging disease threats. When funding rules become unpredictable, the people who suffer are the patients waiting for that cancer drug, the community health worker whose program loses support mid-year, the graduate student whose research grant vanishes for reasons unrelated to the quality of their work.

The stopgap bill buys time, not resolution. OMB had planned to finalize its rule by Oct. 1, and nothing in this week's legislation stops the agency from trying again once the current funding measure lapses in December. Researchers, hospitals and patient advocates who spent the summer flooding OMB with comments will need to stay engaged through the fall, because the underlying question, whether science funding should answer to peer review or to political appointees, remains unsettled. For now, the labs keep their lights on. Whether that lasts past the holidays is anyone's guess.